Business

Moderna’s experimental vaccine prevents cancer recurrence, in ‘historic’ win for personalized medicine. Its stock is soaring.

MarketWatch · August 19, 2026 at 10:16 AM

Moderna’s experimental vaccine prevents cancer recurrence, in ‘historic’ win for personalized medicine. Its stock is soaring.

The candidate is a combination of an mRNA therapeutic vaccine and Merck’s cancer drug Keytruda.

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.marketwatch.com — the content belongs to MarketWatch.

Moderna’s experimental vaccine prevents cancer recurrence, in ‘historic’ win for personalized medicine. Its stock is soaring.

More from MarketWatch

I want to be a snowbird, but I’m not sure my $2 million nest egg can sustain two homes

‘Too many people go bankrupt’: Should Medicare provide catastrophic coverage?

Marvell’s stock pops on news of Google chip deal — and Broadcom’s falls

Should you Venmo your kid’s college tuition? Here’s what to know as schools add new payment options.

More in Business

I want to be a snowbird, but I’m not sure my $2 million nest egg can sustain two homes

‘Too many people go bankrupt’: Should Medicare provide catastrophic coverage?

We're booking a five-fold profit on one of drug stock's rally to record highs

Treasury doubles debt buybacks as Bessent moves to steady bond market

Marvell pops 6% on AI chip deal that lets Google buy up to $12.2 billion in shares

Take a look inside Miami's top 3 elite schools where billionaires send their kids